This invention relates generally to a method of identifying an individual having an increased susceptibility to developing Familial Primary Pulmonary Hypertension (FPPH), as well as to a method for diagnosing an individual suffering from FPPH. The invention also relates to a method of identifying an individual having an increased susceptibility to developing (non-familial) Primary Pulmonary Hypertension (PPH), as well as to a method for diagnosing an individual suffering from PPH.
An isolated nucleic acid encoding the Helicobacter pylori recombinase comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. Also provided is an isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 1 under stringent conditions and has at least 70% complementarity with the segment of the nucleic acid of SEQ ID NO:1 to which it hybridizes. Also provided is a mutant strain of H. pylori that does not express a functional recombinase (recA.sup.- mutant). An immunogenic amount of the recA.sup.- mutant H. pylori in a pharmaceutically acceptable carrier is provided. A method of immunizing a subject against infection by H. pylori comprises administering to the subject an immunogenic amount of mutant H. pylori in a carrier for the mutant.
In 2009 over 70,000 American were diagnosed with urinary bladder cancer, and in that same year over 14,000 Americans died of bladder cancer. Low funding for bladder cancer helps explain the slow progress in both the identification of biomarkers and the development of new treatments for metastatic bladder cancer. Nonetheless, novel diagnostic biomarkers are needed to aid in the early identification of patients with bladder cancer, and also to determine which patients are likely to progress. Vanderbilt researchers have identified such a biomarker whose expression is reduced and lost during progression of bladder cancer.
Vanderbilt engineers have developed a robust platform for point-of-care (POC) diagnostics applicable to infectious diseases, biowarfare agents and environmental and agricultural testing. This technology uses capture antibodies on a polyester filament, or DNA, on a gold wire that act as molecular hooks to troll for viral or bacterial protein antigens, RNA or capture DNA present in a small biological sample solution. It is envisioned that once the analytical POC device is purchased, a different single-use filament would be sold for each pathogen test of interest.
Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g., anxiety, epilepsy, schizophrenia and other psychotic disorders, Parkinson's disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5 antagonist compound of the invention.
This technology relates to a device and method for non-invasive evaluation of a target of interest of a living subject, and in particular to devices and methods that integrate confocal imaging with confocal Raman spectroscopy, for non-invasive evaluation of the biochemical compositions and morphological details of normal and cancerous skin lesions of a living subject.
Age-related Macular Degeneration (AMD) is the leading cause of blindness in elderly patients in developed countries, affecting approximately 7.5 million Americans. Recently several genetic and environmental factors have been implicated as susceptibility factors. We have developed an algorithm which can incorporate all of the risk factors a patient may have and determine a risk value for which they may be susceptible for developing AMD. Currently there is no predictive test for identifying individuals that are at risk for developing AMD rather individuals are screened after the age of 60 for the presence of the disease. This test would allow individuals who are at risk of developing AMD to be identified prior to onset of the disease so that preventative steps may be taken and delay or prevent AMD from occurring.
Late-Onset Alzheimer's Disease (LOAD) is a complex disorder with a strong genetic component. Previous studies suggest that genetic variants contribute to not just LOAD susceptibility, but to the variation of the age-at-onset (AAO). Millions of people suffer from this disease but until now there has been no way to predict the probably age at which the disease would begin to manifest. A genome-wide analysis of multitude of single nucleotide polymorphism (SNP's) was performed on a large population of patients. The importance of identifying SNP's that are associated with a disease allows the comparison on regions of the genome between affected and non-affected individuals. When strong associations are made they allow us to predict the likelihood of an individual being affected by the disease. In this case not only the disease but a prediction of the age at which the individual will be affected can be predicted.
Autism is a brain development disorder characterized by impaired social interaction, impaired communication, and restricted and repetitive behavior, all starting before a child is three years old. Autism has a strong genetic basis, although the genetics of autism are complex and it is unclear whether autism is explained more by multigene interactions or by rare mutations. Vanderbilt and University of Miami researchers have identified a small nucleotide polymorphisms (SNP) on chromosome 5 which associates with autism. This SNP could be developed for early detection of this disease. Diagnosis of autism can be difficult and typically not done until children have difficulty with social interactions. If autism could be identified at an earlier stage then behavior modifications could be introduced to help children preventing many of the restrictive behavior these children have.
Approximately 5% of patients administered gentamicin, a common antibiotic, experience vestibular ototoxicity, or poisoning of the inner ear resulting in balance dysfunction such as vertigo, dizziness, and imbalance. Vanderbilt researchers and University of Maryland researchers have identified three specific polymorphisms in susceptible genes that are associated with this disorder. These results maybe used for personalized medicine such that a patient could be screened prior to administering the drug allowing the physician to alter the treatment plan for patients that would be at an increased risk for developing this disorder.
This technology provides for a proteomic approach to grading gliomas, and for predicting patient survival. In addition to employing global protein expression patterns, such as by mass spectrometry, particular target proteins whose expression is altered in various gliomas can be used to predict the stage/classification of a glioma, as well as to indicate whether a given patient will be a short- or long-term survivor.
This technology provides for the simultaneous assessment of multiple tissue regions or microregions, the benefit being homogeneity of the sampling, both in terms of tissue content and timing. Discrete regions of a tissue sample, such as those demarcated by microwells formed within the tissue itself or tissue plugs removed from the tissue in a spatially referenced fashion, can be treated with one or more physical or chemical treatments to liberate target molecules of interest. Subsequent analysis of said target molecules by, e.g., mass spectroscopy, permits identification of a variety of biological parameters, including those associated with disease or therapy.